These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
59 related articles for article (PubMed ID: 33130694)
1. [Multidisciplinary Therapy for Unresectable Pancreatic Cancer]. Mashiko T; Nakano A; Masuoka Y; Yamamoto S; Ozawa S; Nakagohri T Gan To Kagaku Ryoho; 2020 Sep; 47(9):1331-1335. PubMed ID: 33130694 [TBL] [Abstract][Full Text] [Related]
2. [Multidisciplinary Therapy with Gemcitabine and Nab-Paclitaxel for Unresectable Pancreatic Cancer]. Motoi F; Takadate T; Maeda S; Ariake K; Masuda K; Ishida M; Fukase K; Mizuma M; Ohtsuka H; Sakata N; Hayashi H; Nakagawa K; Morikawa T; Naitoh T; Unno M Gan To Kagaku Ryoho; 2017 Nov; 44(12):1241-1244. PubMed ID: 29394594 [TBL] [Abstract][Full Text] [Related]
3. The prognostic impact of tumour location and first-line chemotherapy regimen in locally advanced pancreatic cancer. Takeda T; Sasaki T; Mie T; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N Jpn J Clin Oncol; 2021 Apr; 51(5):728-736. PubMed ID: 33611490 [TBL] [Abstract][Full Text] [Related]
4. [Outcomes of FOLFIRINOX as First-Line Treatment for Recurrent or Unresectable Pancreatic Cancer]. Tsujie M; Fumita S; Ishikawa H; Kitani K; Satoi S; Fukuda S; Manabe H; Akashi Y; Wakasa T; Shiono H; Tamura T; Yukawa M; Inoue M Gan To Kagaku Ryoho; 2019 Aug; 46(8):1259-1263. PubMed ID: 31501367 [TBL] [Abstract][Full Text] [Related]
5. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plus nab-paclitaxel chemotherapy: A case report. Yokota T; Takano S; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Nakadai E; Ohtsuka M Mol Clin Oncol; 2019 Apr; 10(4):419-424. PubMed ID: 30931110 [TBL] [Abstract][Full Text] [Related]
6. Survival benefit of conversion surgery for patients with initially unresectable pancreatic cancer who responded favorably to nonsurgical treatment. Asano T; Hirano S; Nakamura T; Okamura K; Tsuchikawa T; Noji T; Nakanishi Y; Tanaka K; Shichinohe T J Hepatobiliary Pancreat Sci; 2018 Jul; 25(7):342-350. PubMed ID: 29797499 [TBL] [Abstract][Full Text] [Related]
7. Comparison of efficacy and toxicity of FOLFIRINOX and gemcitabine with nab-paclitaxel in unresectable pancreatic cancer. Muranaka T; Kuwatani M; Komatsu Y; Sawada K; Nakatsumi H; Kawamoto Y; Yuki S; Kubota Y; Kubo K; Kawahata S; Kawakubo K; Kawakami H; Sakamoto N J Gastrointest Oncol; 2017 Jun; 8(3):566-571. PubMed ID: 28736643 [TBL] [Abstract][Full Text] [Related]
8. Prognostic factors in conversion surgery following nab-paclitaxel with gemcitabine and subsequent chemoradiotherapy for unresectable locally advanced pancreatic cancer: Results of a dual-center study. Igarashi T; Yamada S; Hoshino Y; Murotani K; Baba H; Takami H; Yoshioka I; Shibuya K; Kodera Y; Fujii T Ann Gastroenterol Surg; 2023 Jan; 7(1):157-166. PubMed ID: 36643365 [TBL] [Abstract][Full Text] [Related]
9. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report. Okura R; Takano S; Yokota T; Yoshitomi H; Kagawa S; Furukawa K; Takayashiki T; Kuboki S; Suzuki D; Sakai N; Nojima H; Mishima T; Miyazaki M; Ohtsuka M Mol Clin Oncol; 2018 Oct; 9(4):389-393. PubMed ID: 30214727 [TBL] [Abstract][Full Text] [Related]
10. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368 [TBL] [Abstract][Full Text] [Related]
11. Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. Kourie H; Auclin E; Cunha AS; Gaujoux S; Bruzzi M; Sauvanet A; Lourenco N; Trouilloud I; Louafi S; El-Hajjar A; Vaillant JC; Smith D; Touchefeu Y; Bachet JB; Pietrasz D; Taieb J Clin Res Hepatol Gastroenterol; 2019 Nov; 43(6):663-668. PubMed ID: 31029644 [TBL] [Abstract][Full Text] [Related]
12. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Aristu J; Cañón R; Pardo F; Martínez-Monge R; Martin-Algarra S; Manuel Ordoñez J; Villafranca E; Moreno M; Cambeiro M; Azinovic I Am J Clin Oncol; 2003 Feb; 26(1):30-6. PubMed ID: 12576921 [TBL] [Abstract][Full Text] [Related]
13. Benefits of Conversion Surgery after Multimodal Treatment for Unresectable Pancreatic Ductal Adenocarcinoma. Yanagimoto H; Satoi S; Yamamoto T; Yamaki S; Hirooka S; Kotsuka M; Ryota H; Ishida M; Matsui Y; Sekimoto M Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32486418 [TBL] [Abstract][Full Text] [Related]
14. FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma. Sadot E; Doussot A; O'Reilly EM; Lowery MA; Goodman KA; Do RK; Tang LH; Gönen M; D'Angelica MI; DeMatteo RP; Kingham TP; Jarnagin WR; Allen PJ Ann Surg Oncol; 2015 Oct; 22(11):3512-21. PubMed ID: 26065868 [TBL] [Abstract][Full Text] [Related]
15. Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. Khushman M; Dempsey N; Maldonado JC; Loaiza-Bonilla A; Velez M; Carcas L; Dammrich D; Hurtado-Cordovi J; Parajuli R; Pollack T; Harwood AP; Macintyre J; Tzeng CW; Merchan JR; Restrepo MH; Akunyili II; Ribeiro A; Narayanan G; Portelance L; Sleeman D; Levi JU; Lima CM; Hosein PJ Pancreatology; 2015; 15(6):667-73. PubMed ID: 26412296 [TBL] [Abstract][Full Text] [Related]
16. Preoperative chemotherapy, radiotherapy, and surgical resection of locally advanced pancreatic cancer. Wanebo HJ; Glicksman AS; Vezeridis MP; Clark J; Tibbetts L; Koness RJ; Levy A Arch Surg; 2000 Jan; 135(1):81-7; discussion 88. PubMed ID: 10636353 [TBL] [Abstract][Full Text] [Related]
17. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols. Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229 [TBL] [Abstract][Full Text] [Related]
18. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469 [TBL] [Abstract][Full Text] [Related]
19. FOLFIRINOX-based neoadjuvant chemoradiotherapy for borderline and locally advanced pancreatic cancer: A pilot study from a tertiary centre. Pouypoudat C; Buscail E; Cossin S; Cassinotto C; Terrebonne E; Blanc JF; Smith D; Marty M; Dupin C; Laurent C; Dabernat S; Chiche L; Vendrely V Dig Liver Dis; 2019 Jul; 51(7):1043-1049. PubMed ID: 31000479 [TBL] [Abstract][Full Text] [Related]
20. Development of chemotherapy and significance of conversion surgery after chemotherapy in unresectable pancreatic cancer. Furuse J; Shibahara J; Sugiyama M J Hepatobiliary Pancreat Sci; 2018 May; 25(5):261-268. PubMed ID: 29651809 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]